DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia. (27th March 2014)

• Record Type: Journal Article
• Authors: van der Sligte, Naomi E.; Krumbholz, Manuela; Pastorczak, Agata; Scheijen, Blanca; Tauer, Josephine T.; Nowasz, Christina; Sonneveld, Edwin; de Bock, Geertruida H.; Meeuwsen‐de Boer, Tiny G. J.; van Reijmersdal, Simon; Kuiper, Roland P.; Bradtke, Jutta; Metzler, Markus; Suttorp, Meinolf; de Bont, Evelina S. J. M.; van Leeuwen, Frank N.
• Is Part Of: British journal of haematology. Volume 166:Number 2(2014:Jul.)
• Page Start: 250
• Page End: 253
• Publication Date: 2014-03-27
• Subjects: paediatric CML -- lymphoid blast crisis -- copy number alterations -- IKZF1; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.12850
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Early recognition of children with chronic phase chronic myeloid leukaemia (CML‐CP) at risk for developing a lymphoid blast crisis (LyBC) is desirable, because therapy options in CML‐LyBC are limited. We used Multiplex Ligation‐dependent Probe Amplification to determine whether B‐cell lymphoid leukaemia‐specific copy number alterations (CNAs) (e.g. IKZF1, PAX5, CDKN2A deletions) could be detected in CML‐CP and may be used to predict disease progression to LyBC. CNAs were detected in all patients with CML‐LyBC, but in none of the 77 patients with CML‐CP. Based on this study we conclude that CNAs remain a hallmark of disease progression.